Pentax, Motus GI & more — 4 GI company key notes

Here are four updates on GI companies from the past week:

Advertisement

Theravance Biopharma Ireland and Janssen Biotech entered into a co-development and commercialization agreement over TD-1473, an inflammatory intestinal disease inhibitor.

Motus GI will sell 4.25 million shares of its common stock at $6 per share as it attempts to raise $25.5 million through a U.S.-based initial public offering

The FDA and Pentax announced a voluntary recall of all ED-3490TK video duodenoscopes to replace a series of parts and update the operations manual.

Ferring Pharmaceuticals’ low-volume bowel preparation Clenpiq is now available in the U.S. via prescription.

More articles on gastroenterology:
UroLife designates Midtown Urology Associates a UroLife Center of Excellence: 3 insights
The definition of ‘outpatient’ ACDF and lumbar discectomy procedures can be misleading: 5 insights
Senate report: 5 opioid manufacturers paid $9M to 14 patient advocacy groups — 8 insights

At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.

Advertisement

Next Up in GI & Endoscopy

  • Birmingham (Ala.) Gastroenterology has opened a clinic in Jasper, Ala., expanding access to digestive health services in the region, the…

  • Premier Health Partners has acquired Dayton, Ohio-based Digestive Specialists, according to a notice posted on the website of law firm…

Advertisement

Comments are closed.